Could the gut epithelium be a new target for antidepressants?
Researchers have discovered new connections between the gut and brain that hold promise for more targeted treatments for depression and anxiety.
The findings could also help prevent digestive issues in children by limiting the transmission of antidepressants during pregnancy.
The study, published in the journal Gastroenterology, shows that increasing serotonin in the gut epithelium improves symptoms of anxiety and depression in animal studies.
The researchers also found that, in humans, antidepressant use during pregnancy increases the risk of babies developing constipation in the first year of life.
“Our findings suggest that there may be an advantage to targeting antidepressants selectively to the gut epithelium, as systemic treatment may not be necessary for eliciting the drugs’ benefits but may be contributing to digestive issues in children exposed during pregnancy,” said Kara Margolis, Director of the NYU Pain Research Center and Associate Professor of Molecular Pathobiology at NYU College of Dentistry, who co-led the study with Mark Ansorge, Associate Professor of Clinical Neurobiology at Columbia University.
Limitations with current treatment
Many people with mood disorders also experience disorders of gut-brain interaction (DGBI), digestive issues such as irritable bowel syndrome and functional constipation that result from communication issues between the gut and brain.
Antidepressants – including selective serotonin reuptake inhibitors, or SSRIs – are widely prescribed for depression, anxiety, and DGBIs. While these drugs are generally considered to be safe, they can come with side effects such as gastrointestinal issues and anxiety, which may lead people to stop taking the medication.
Antidepressants also pose challenges during and after pregnancy because of their ability to pass through the placenta and breast milk. Some studies show a higher incidence of mood and cognitive disorders in children exposed to SSRIs during pregnancy, although other studies have conflicting results.
Untreated depression and anxiety during pregnancy have known risks for both the mother and baby, so expectant mothers have to weigh the potential risks of taking medication with their mental health needs.
SSRIs work by blocking a protein called the serotonin transporter, raising serotonin levels in the brain. However, the vast majority of the body’s serotonin is produced in the gut, and the serotonin transporter also lines the intestines.
“For psychiatric medications that act on receptors in the brain, many of those same receptors are in the gut, so you have to consider the effects on gut development and function,” said Margolis, who is also an Associate Professor of Pediatrics and Cell Biology at NYU Grossman School of Medicine.
Removing the serotonin transporter
Previous studies led by Margolis found that mice bred to lack the serotonin transporter throughout the body, as well as mice that were exposed to SSRIs during and after pregnancy, experienced changes in the development of the digestive system and dysfunction in motility in the gut.
In the new study, the researchers studied mice lacking the serotonin transporter in the gut epithelium either during development (mimicking exposure to an SSRI during pregnancy) or in young adulthood (akin to taking an SSRI as an adult).
Removing the serotonin transporter from the gut epithelium increased serotonin levels and led to improvements in anxiety and depression symptoms in both groups of mice. It also spared them from the adverse effects on digestion and motility that were found in the previous research where the serotonin transporter was missing or blocked throughout the body.
The researchers also determined that vagus nerves are the path by which serotonin in the gut epithelium modulates mood. Cutting off this communication in mice from gut to brain removed improvements in anxiety and depression.
In addition, the team studied more than 400 pairs of mothers – a quarter of whom were taking antidepressants (SSRIs or SNRIs) – and their babies, and followed them during pregnancy and throughout the children’s first year of life.
The use of antidepressants during pregnancy significantly increased the risk of a child experiencing functional constipation during their first year of life.
“We found that, at the age of one, 63% of children exposed to antidepressants during pregnancy experienced constipation, compared with 31% of children whose mothers did not take medication,” said Larissa Takser, Professor of Pediatrics at the Université de Sherbrooke in Québec. “This finding suggests a potential connection between serotonin levels in utero and gut development, and opens new doors to examine SSRI properties not previously studied.”
Diana Spencer, Senior Digital Content Editor, DDW
